ArticleThe oncologist2023

A Phase Ib/II Study of WNT974 + Encorafenib + Cetuximab in Patients With BRAF V600E-Mutant KRAS Wild-Type Metastatic Colorectal Cancer.

Josep Tabernero et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.